intranasal glutathione nasal spray MintRX – Pharmacy-Grade Antioxidant Boost Instructions for Glutathione Nasal Spray

This method accurately identifies the characteristic ion peaks of 5amino1mq and effectively eliminates interference from excipients and impurities

P.ReddyV

Lau DCW, et al

The Phase 1 trial of DA-1726 is progressing well, and we expect to both dose the first patient in the multiple ascending dose (MAD) Part 2 and read-out top-line data from the single ascending dose (SAD) Part 1 in the third quarter of this year, with top-line data from the MAD Part 2 expected in the first quarter of 2025." Abstract Title: DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Obesity Treatment and Lipid Management Presenter Name: Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center Authors: Tae-Hyoung Kim, Il-Hun Jung, Su Jin Lee, Hyung Heon Kim, Mi-Kyung Kim, Yuna Chae Abstract Number: 2024-LB-5728 Poster Presentation Number: 2058-LB Session: 23-A Obesity-Animal Session Date: Saturday, June 22, 2024 Session Time: 12:30 pm 1:30 pm ET DA-1726 is currently in a Phase 1 clinical trial